FOXD3 regulates anaplastic thyroid cancer progression
暂无分享,去创建一个
D. Song | T. Meng | Lei Zhou | Huabin Yin | Mengjun Hu | Xiufang Li | Haiyan Chen | F. Zhao | Yundong Li
[1] Min Zhang,et al. Human biliverdin reductase promotes EMT through the ERK1/2 signal pathway in breast cancer. , 2016, European journal of pharmacology.
[2] F. Han,et al. FOXO4 and FOXD3 are predictive of prognosis in gastric carcinoma patients , 2016, Oncotarget.
[3] Xiaoping Zhou,et al. FOXD3 suppresses tumor growth and angiogenesis in non-small cell lung cancer. , 2015, Biochemical and biophysical research communications.
[4] W. Du,et al. Decreased FOXD3 Expression Is Associated with Poor Prognosis in Patients with High-Grade Gliomas , 2015, PloS one.
[5] A. Aplin,et al. FOXD3 Modulates Migration through Direct Transcriptional Repression of TWIST1 in Melanoma , 2014, Molecular Cancer Research.
[6] J. Yun,et al. FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2 , 2014, Oncotarget.
[7] Xuan Sun,et al. FoxD3 deficiency promotes breast cancer progression by induction of epithelial-mesenchymal transition. , 2014, Biochemical and biophysical research communications.
[8] Yongxiang Yin,et al. Downregulation of the transcription factor, FoxD3, is associated with lymph node metastases in invasive ductal carcinomas of the breast. , 2014, International journal of clinical and experimental pathology.
[9] Kai Huang,et al. FOXD3 is a novel tumor suppressor that affects growth, invasion, metastasis and angiogenesis of neuroblastoma , 2013, Oncotarget.
[10] V. D. Di Crescenzo,et al. Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review , 2013, BMC Surgery.
[11] M. Xing,et al. Molecular pathogenesis and mechanisms of thyroid cancer , 2013, Nature Reviews Cancer.
[12] K. Bible,et al. Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches , 2011, Expert opinion on investigational drugs.
[13] A. Aplin,et al. FOXD3 Regulates Migration Properties and Rnd3 Expression in Melanoma Cells , 2011, Molecular Cancer Research.
[14] M. Todaro,et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells. , 2010, Cancer research.
[15] A. Aplin,et al. FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells. , 2010, Cancer research.
[16] M. Shah,et al. Review: Thyroid cancer: emerging role for targeted therapies , 2010, Therapeutic advances in medical oncology.
[17] B. Nelkin,et al. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. , 2009, The Journal of clinical endocrinology and metabolism.
[18] J. Copland,et al. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. , 2008, Endocrine-related cancer.
[19] Pei-Wen Wang,et al. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan. , 2004, Thyroid : official journal of the American Thyroid Association.
[20] M. Goulding,et al. The winged-helix transcription factor Foxd3 suppresses interneuron differentiation and promotes neural crest cell fate. , 2001, Development.
[21] A. Müller,et al. FoxD3 is a novel, epigenetically regulated tumor suppressor in gastric carcinogenesis. , 2013, Gastroenterology.
[22] Jun Yu,et al. Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis. , 2013, Gastroenterology.
[23] D. Goldenberg,et al. Molecular and genetic markers of follicular-cell thyroid cancer: etiology and diagnostic and therapeutic opportunities. , 2013, Advances in experimental medicine and biology.